Drugs.com - Clinical Trials

Novo Nordisk's Mim8 Prophylaxis Treatment Shown to be Well-Tolerated When Switching from Emicizumab in People with Hemophilia A in New Phase 3 Data

Bagsværd, Denmark, 22 June 2025 – Novo Nordisk today presented results from the phase 3b FRONTIER5 trial showing that a direct switch to investigational Mim8 (denecimig) prophylaxis from emicizumab treatment, without a washout period or...

Jun 23, 2025 - 00:20
 0
Novo Nordisk's Mim8 Prophylaxis Treatment Shown to be Well-Tolerated When Switching from Emicizumab in People with Hemophilia A in New Phase 3 Data
Bagsværd, Denmark, 22 June 2025 – Novo Nordisk today presented results from the phase 3b FRONTIER5 trial showing that a direct switch to investigational Mim8 (denecimig) prophylaxis from emicizumab treatment, without a washout period or...
Read More

Tags:

Previous Article

Why Your AWD Vehicle Needs Matching Tires, And What Happens If They're Not The Same

Next Article

Lilly's Once-Weekly Insulin Efsitora Alfa Demonstrated A1C Reduction and a Safet...

Related Posts

Rilzabrutinib Granted Orphan Drug Designation in the US for Sickle Cell Disease

Rilzabrutinib Granted Orphan Drug Designation in the US...

Jun 3, 2025  0

Teva Celiac Disease Candidate TEV-53408 Granted Fast Track Designation by US FDA

Teva Celiac Disease Candidate TEV-53408 Granted Fast Tr...

May 30, 2025  0

Johnson & Johnson Unveils First-in-Human Results for Pasritamig, Showing Early Anti-Tumor Activity in Prostate Cancer

Johnson & Johnson Unveils First-in-Human Results for Pa...

Jun 3, 2025  0